Newsfeeds - Spark Newswire

1 minute read

Century Therapeutics Receives Study May Proceed Notification From FDA For CNTY-101

Today, 7:53 AM

– Investigational New Drug Application for CNTY-101, a CAR-iNK product candidate targeting CD19 for B-cell malignancies, cleared by FDA – – First cell product candidate engineered with six

IPSC

1 minute read

Piper Sandler Maintains Overweight on Century Therapeutics, Lowers Price Target to $22

By Benzinga Newsdesk

Today, 7:53 AM

Piper Sandler analyst Edward Tenthoff maintains Century Therapeutics (NASDAQ:IPSC) with a Overweight and lowers the price target from $38 to $22.

IPSC

57 minute read

Stocks That Hit 52-Week Lows On Friday

By Benzinga Insights

Today, 7:53 AM

On Friday, 1043 companies hit new 52-week lows.

AAOI

1 minute read

SVB Leerink Maintains Outperform on Century Therapeutics, Lowers Price Target to $27

By Benzinga Newsdesk

Today, 7:53 AM

SVB Leerink analyst Daina Graybosch maintains Century Therapeutics (NASDAQ:IPSC) with a Outperform and lowers the price target from $32 to $27.

IPSC

1 minute read

Century Therapeutics FY21 Net Loss $95.8M; Ending Cash Position $358.8M

By Bill Haddad

Today, 7:53 AM

Century Therapeutics (NASDAQ:IPSC) will report on Q4 2021.

IPSC

2 minute read

2 Natural-Killer Cell Therapy Oncology Companies Investors Should Watch

By Shanthi Rexaline

Today, 7:53 AM

Natural-killer cell therapy is one of the most recent paradigms in cancer treatment, and two prominent companies working on this new technology are Fate Therapeutics Inc (NASDAQ: FATE) and Century Therapeutics Inc (NASDAQ:

BMY

5 minute read

60 Biggest Movers From Yesterday

By Lisa Levin

Today, 7:53 AM

Gainers Bone Biologics Corporation (NASDAQ: BBLG) shares surged 57.1% to close at $5.39 on Monday.

AACG

4 minute read

45 Stocks Moving In Monday’s Mid-Day Session

By Lisa Levin

Today, 7:53 AM

Gainers Bone Biologics Corporation (NASDAQ: BBLG) shares climbed 71.5% to $5.88.

AACG

1 minute read

Bristol Myers, Century Therapeutics Ink Pact For iPSC-Derived Allogeneic Cell Therapies

By Vandana Singh

Today, 7:53 AM

Century Therapeutics Inc (NASDAQ: IPSC) and Bristol Myers Squibb Co (NYSE: BMY) have announced a

BMY

2 minute read

Century Therapeutics And Bristol Myers Squibb Enter Into A Strategic Collaboration To Develop iPSC-derived Allogeneic Cell Therapies

By Benzinga Newsdesk

Today, 7:53 AM

Collaboration brings together Century’s industry leading iPSC-derived allogeneic cell therapy platform with Bristol Myers Squibb’s expertise in cell therapy and oncology drug development First two programs

BMY